Boulder Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Boulder Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$8K	Buy	+200	New	+$10.6K	0.01%	79

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Boulder Wealth Advisors's CRSP Position: Q4 2022 in Review

Boulder Wealth Advisors opened a new position in CRISPR Therapeutics (CRSP) in Q4 2022: 200 shares worth $8K. The stake represents 0.01% of the portfolio and ranks #79 among its holdings.

398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

Boulder Wealth Advisors held 200 shares of CRISPR Therapeutics worth $8K as of Q4 2022.
CRISPR Therapeutics was a new Boulder Wealth Advisors position in Q4 2022.
CRISPR Therapeutics made up 0.01% of Boulder Wealth Advisors's portfolio in Q4 2022, its #79 holding.
398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on Boulder Wealth Advisors's 13F filing for Q4 2022, filed 21 Feb 2023.